

IN THE SPECIFICATION:

At page 5, please amend lines 4-6, and lines 8-9, by deleting reference to ATCC, as indicated in the following paragraph:

--In one embodiment, the inhibitory signal-generating pharmaceutical composition's agent can be an anti- MAFA antibody. The anti- MAFA antibody can be an antibody that specifically binds to human MAFA. The anti-MAFA antibody can have the same antigen binding specificity as an antibody produced by a hybridoma designated as 7B5 (ATCC ____), or, the anti- MAFA antibody can be produced by a hybridoma designated as 7B5 (ATCC ____). In alternative embodiments, the anti- MAFA antibody is an antibody that specifically binds to human MAFA, the anti-MAFA antibody has the same antigen binding specificity as an antibody produced by a hybridoma designated as 1F10 (ATCC ____), and, the anti- MAFA antibody can be produced by a hybridoma designated as 1F10 (ATCC ____).--

At page 7, please amend lines 19-20, and lines 22-23, by deleting reference to ATCC, as indicated in the following paragraph:

--In one embodiment, the inhibited the anti- MAFA antibody is an antibody that specifically binds to human MAFA. In alternative embodiments, the anti-MAFA antibody has the same antigen binding specificity as an antibody produced by a hybridoma designated as 7B5 (ATCC ____); the anti- MAFA antibody is produced by a hybridoma designated as 7B5 (ATCC ____); the anti- MAFA antibody is an antibody that specifically binds to human MAFA, and the anti-MAFA antibody has the same antigen binding specificity as an antibody produced by a hybridoma designated as 1F10 (ATCC ____); and, the anti- MAFA antibody is produced by a hybridoma designated as 1F10 (ATCC ____).--